Infographics

» inflammation, cancer and drug development

Most Recent

image: Infographic: Repurposing Strategies

Infographic: Repurposing Strategies

By | January 1, 2017

Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.

0 Comments

image: Immune Influence

Immune Influence

By | April 1, 2016

In recent years, research has demonstrated that microbes living in and on the mammalian body can affect cancer risk, as well as responses to cancer treatment.

0 Comments

image: Metabolic Reprogramming

Metabolic Reprogramming

By | April 1, 2016

How cancer cells fuel their rapid growth

0 Comments

image: Under Pressure

Under Pressure

By | April 1, 2016

The causes and consequences of physical forces in the tumor microenvironment

0 Comments

image: A Complex Disorder

A Complex Disorder

By , , and | November 1, 2015

Factors that likely contribute to obesity include disruptions to intercellular signaling, increased inflammation, and changes to the gut microbiome.  

0 Comments

image: Not Immune to Fat

Not Immune to Fat

By | November 1, 2015

The effect of a high-fat diet on murine T cells

0 Comments

image: Ubiquitin Chains in Action

Ubiquitin Chains in Action

By | July 1, 2012

Present in every tissue of the body, ubiquitin appears to be involved in a dizzying array of functions, from cell cycle and division to organelle and ribosome biogenesis, as well as the response to viral infection. The protein plays at least two role

0 Comments

image: Delivering New Genes

Delivering New Genes

By | June 1, 2012

Gene therapies typically involve the introduction of genetic material into target cells to replace or supplement an existing, usually dysfunctional, gene. 

0 Comments

image: Telomere Basics

Telomere Basics

By | May 1, 2012

Telomeres are repetitive, noncoding sequences that cap the ends of linear chromosomes. They consist of hexameric nucleotide sequences (TTAGGG in humans) repeated hundreds to thousands of times. 

4 Comments

image: Designing Transition-State Inhibitors

Designing Transition-State Inhibitors

By | May 1, 2012

A transition-state mimic has the power to bind an enzyme at its tipping point as strongly as any available inhibitor and more strongly than most, preventing enzymatic activity. 

0 Comments

Popular Now

  1. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  2. Henrietta Lacks’s Family Seeks Compensation
  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham